Small-Diameter Balloon Catheter Designed for Pre-Dilatation of Tight,
Calcified CTO Lesions That Require Best Crossability
HONG KONG, April 7, 2008 /PRNewswire/ -- OrbusNeich today announced that it has received CE Mark approval for the Sapphire(TM) 1.25mm PTCA dilatation catheter.
Slated for immediate roll-out to the interventional cardiology community, Sapphire 1.25mm is a small-diameter balloon catheter designed specifically for the pre-dilatation of tight, calcified chronic total occlusion (CTO) lesions that require the best crossability. The product provides physicians with enhanced pushability and superior kink resistance. The Sapphire 1.25mm is the only balloon available in a 5mm length. In addition, 8mm, 10mm and 15mm lengths are also offered.
"The Sapphire 1.25mm balloon is easily deliverable with good pushability, and may be considered a first choice in highly stenotic lesions," said Professor Tan Huay Cheem of the University Hospital in Singapore.
OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. The company's product portfolio includes the Genous(TM) Bio-engineered R stent(TM), an antibody-coated device that is the first-ever stent to capture a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process following placement. Other products are stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent(TM), Sapphire(TM), Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.
A global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; Tokyo; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, today supplies products to interventional cardiologists in more than 60 countries. For more information, visit http://www.OrbusNeich.com.
Copyright©2008 PR Newswire.
All rights reserved